First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Carcinoma, Ovarian Epithelial Clinical Trial

— IOLANTHE  

Official title:

A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06121401
• Other study ID #: IRFMN-OVA-8542
• Status: Recruiting
• Phase: Phase 4
• Start date: September 15, 2023
• Est. completion date: September 15, 2027

Study information

• Verified date: November 2023
• Source: Mario Negri Institute for Pharmacological Research
• Contact: Elena Biagioli
• Phone: +39 0239014650
• Email: iolanthe[@]marionegri.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this prospective, phase IV, multi-centre clinical trial is to to define the proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive who will be treated at first line with olaparib in combination with bevacizumab as maintenance and to describe their clinical and demographic characteristics. Other primary objective is to confirm, in a setting close to clinical practice, the efficacy of olaparib concomitant with bevacizumab as maintenance treatment after first-line chemotherapy in patients with advanced high grade EOC HRD-positive and who have received bevacizumab in combination with chemotherapy.

Description:

This phase IV study will include two translational research projects:

1. The analyses of the circulating-tumor DNA (ctDNA) derived from plasma samples collected at different time points (liquid biopsy). This sub-study has the aim to evaluate and monitor, through the Next Generation Sequencing approach, the evolution of the disease and the changes in the mutational status of HR-related genes which could lead to different PARPi sensitivity (Translational study no.1).

2. The generation of organotypic models that include cancer stem cells to compare the response of these cancer stem cells to that of bulk tumor cells. This approach will be hopefully able to predict the response to PARPi in ovarian cancer patients. (Translational study no.2)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 190
• Est. completion date: September 15, 2027
• Est. primary completion date: March 15, 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patient who has completed first line platinum-taxane chemotherapy

2. Patient on treatment with bevacizumab (patient must have received at least 1 cycle of bevacizumab in combination with chemotherapy). Bevacizumab treatment should have been administered at a dose of 15mg/kg q3 weeks.

3. Patient must be without evidence of disease (NED) or in complete response (CR) or partial response (PR) from her first line treatment.

4. Patients with histologically confirmed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer and HRD-positive tumor according to the Myriad Mychoice CDx Plus evaluation.

5. Patients must have normal organ and bone marrow function values measured within 28 days before administration of olaparib

6. Normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP = 140 mmHg and/or diastolic BP = 90 mmHg

8. Patients must have a life expectancy = 16 weeks. 9. Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of olaparib administration and confirmed the day of treatment start.

Exclusion Criteria:

1. Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia

2. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.

3. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required

4. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.

5. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

6. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).

7. Patients with known active hepatitis (i.e. Hepatitis B or C).

8. Any previous treatment with PARP inhibitor, including Olaparib.

9. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to olaparib.

10. Major surgery within 2 weeks of starting olaparib and patients must have recovered from any effects of any major surgery

11. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).

12. Concomitant use of known strong CYP3A inhibitors

13. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers

14. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).

15. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

16. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of olaparib or puts the patient at high risk for treatment-related complications.

17. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

18. Breast feeding and pregnant women

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial

Intervention

Drug:
• Olaparib
Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
• Bevacizumab
Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks

Locations

Country	Name	City	State
Italy	Istituto Oncologico Veneto IRCCS	Padova
Italy	Azienda Socio Sanitaria Territoriale (ASST) Lariana	San Fermo Della Battaglia	Como

Sponsors (2)

Lead Sponsor	Collaborator
Mario Negri Institute for Pharmacological Research	AstraZeneca

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients treated with olaparib	Define the proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive who will be treated at first line with olaparib in combination with bevacizumab as maintenance and to describe their clinical and demographic characteristics	42 months
Primary	Efficacy of olaparib	Confirm, in a setting close to clinical practice, the efficacy of olaparib concomitant with bevacizumab as maintenance treatment after first-line chemotherapy in patients with advanced high grade EOC HRD-positive and who have received bevacizumab in combination with chemotherapy. The efficacy will be evaluated in terms of PFS rate at 24 months. PFS will be defined as the time from the start of olaparib therapy until disease progression or death whichever comes first	42 months